Business Overview: AbCellera Biologics Inc. (NASDAQ: ABCL)

---

Executive Summary

AbCellera Biologics Inc. is a Vancouver-headquartered, clinical-stage biotechnology company that built its business over 15 years and roughly $1 billion of investment as an antibody discovery engine for pharmaceutical partners, and has since pivoted toward developing its own internal drug pipeline while continuing to collect milestone payments and royalties from a large existing portfolio of partnered programs.

AbCellera generates modest trailing revenue of roughly $66 million against a net loss of about $165 million, reflecting a company still investing heavily to transition from a platform/royalty business into a clinical-stage drug developer. Despite the losses, the market has assigned AbCellera a market capitalization of roughly $3.5 billion, reflecting the perceived long-term optionality in both its royalty portfolio and its emerging internal pipeline.

---

1. Core Business Model & How They Work

AbCellera's business rests on a proprietary, AI/machine-learning-integrated antibody discovery platform capable of finding antibodies against historically difficult target classes (notably GPCRs and ion channels) and building multispecific antibodies such as T-cell engagers. The company monetizes this platform through two channels:

1. Partner royalty/milestone portfolio — Historically, pharmaceutical partners brought AbCellera a therapeutic target, and AbCellera used its discovery platform to find and optimize antibody candidates in exchange for downstream milestone payments and royalties (averaging 3.3% across all 104 partner-initiated programs launched through year-end 2025, and 4.2% on more recent 2020–2025 contracts). This is a capital-light, long-duration royalty stream tied to partner drugs' eventual clinical and commercial success.
2. Internal drug pipeline — Since roughly 2023, AbCellera has deliberately reduced new discovery-partnership volume to redirect resources into developing and owning its own drug candidates (ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis are already in clinical trials, with two more in IND-enabling activities), aiming to capture far more economic value per successful drug than a royalty alone would provide.

The 2025 completion of a 130,000-square-foot clinical GMP manufacturing facility gives AbCellera direct control over its own clinical drug supply chain — a capability-intensive move that supports both intellectual property protection and faster internal pipeline execution.

---

2. Business Segments

AbCellera does not report formal financial segments; it operates as a single integrated antibody discovery and development business, viewed through two lenses:

• Partner-Driven Discovery Programs — 104 partner-initiated programs launched to date, generating milestone and royalty revenue as partner drugs progress through clinical trials and (for a subset) commercialization.
• Internal Pipeline — proprietary drug candidates that AbCellera discovers, develops, and intends to own outright (or license on favorable terms), starting with vasomotor symptoms and atopic dermatitis indications.

---

3. Product Portfolio

• ABCL635 — internal clinical-stage candidate targeting vasomotor symptoms (e.g., menopausal hot flashes).
• ABCL575 — internal clinical-stage candidate for atopic dermatitis.
• Two additional internal candidates in IND-enabling (pre-clinical) activities.
• Partnered antibody programs — a broad royalty-bearing portfolio spanning oncology, immunology, infectious disease, and other therapeutic areas developed in collaboration with major pharmaceutical partners including Eli Lilly, AbbVie, Regeneron, Novartis, Gilead Sciences, and Moderna.
• Discovery platform/technology licensing capability — the underlying AI-integrated antibody discovery engine itself, including specialized expertise in GPCR/ion channel targeting and multispecific (T-cell engager) antibody design.

---

4. Competitive Landscape

AbCellera's competitive position differs by lens: as a discovery-technology provider it competes with other antibody discovery platforms, while its emerging internal pipeline competes directly with large, well-resourced pharmaceutical companies in each therapeutic indication.

Key competitive dynamics:

• Vasomotor symptoms (ABCL635) — competes against generic hormone replacement therapy and newer non-hormonal options from Astellas and Bayer.
• Atopic dermatitis (ABCL575) — a crowded, high-value immunology indication with approved antibody therapies from Regeneron/Sanofi, Eli Lilly, AbbVie, and Pfizer already on the market, plus clinical-stage competitors including Kyowa Kirin, Apogee Therapeutics, and Bristol-Myers Squibb.
• Antibody discovery platforms — other discovery-technology providers and in-house pharma discovery capabilities compete for the partnership deals that built AbCellera's original royalty portfolio, though the company has intentionally deprioritized new partnerships since 2023.

---

5. Strategic Strengths & Risks

Competitive Strengths

• Deep, differentiated platform built over 15 years and ~$1 billion of investment, with specific strength in historically hard-to-drug target classes (GPCRs, ion channels) and multispecific antibody engineering.
• Large existing royalty portfolio (104 partnered programs with blue-chip pharma partners) provides a long-duration, largely capital-light call option on numerous partner drugs' eventual approval and commercial success, diversifying AbCellera's risk away from any single program.
• In-house clinical GMP manufacturing (130,000 sq ft facility completed 2025) gives AbCellera direct control over supply chain and intellectual property for its internal pipeline, reducing dependence on third-party CDMOs.
• Blue-chip partner roster (Lilly, AbbVie, Regeneron, Novartis, Gilead, Moderna) reflects strong historical validation of the platform's discovery quality.

Strategic Risks

• Continued heavy losses during pipeline pivot — the shift from a royalty-focused model to an internally funded drug developer requires substantial, sustained R&D and clinical trial spending, reflected in the roughly $165 million trailing net loss against just $66 million of revenue.
• Binary clinical trial risk — as AbCellera's internal candidates advance through trials, their success or failure will increasingly drive company value, introducing the classic all-or-nothing risk profile of clinical-stage biotech.
• Crowded competitive indications — both current lead internal programs (vasomotor symptoms, atopic dermatitis) face established, well-capitalized competitors with approved products already generating revenue.
• Reduced new partnership volume — deliberately scaling back new discovery deals since 2023 to focus internally means the royalty portfolio, while valuable, is not being meaningfully replenished with new programs at the prior pace.
• Capital intensity — the newly built GMP manufacturing facility and expanding clinical programs require continued significant capital investment before any internal drug can generate revenue.

---

6. Financial Overview

AbCellera's roughly $3.5 billion market capitalization against just $66 million of trailing revenue reflects a valuation built primarily on the option value of its royalty portfolio and internal pipeline rather than current financial performance.

---

7. Summary Conclusion

AbCellera occupies an unusual position in biotech: a company with a genuinely differentiated, heavily capitalized antibody discovery platform and a broad, blue-chip-partnered royalty portfolio, now mid-transition into becoming a clinical-stage drug developer in its own right. That pivot could substantially increase AbCellera's economic capture per successful program, but it also exposes the company to binary clinical trial risk and crowded competitive indications that its royalty-only predecessor model largely avoided. AbCellera's durability as an investment thesis rests on whether its platform's historical partner-validated discovery quality translates into internal clinical success, and whether the existing royalty portfolio can fund the transition without excessive additional dilution.